GlassScriptPhysician profile
Francine M Phillips
NPI 1962683813
$144,869.11
in general payments reported to CMS, 2019-2025
25 companies · $58K in 2025
The $58K reported for 2025 was more than what 99% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,459 · 2022: $18K · 2023: $27K · 2024: $39K · 2025: $58K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $83K · Consulting Fee: $16K · Travel and Lodging: $15K · Food and Beverage: $11K · Education: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $83,078.75 |
| Consulting Fee | $15,934.50 |
| Travel and Lodging | $14,573.91 |
| Food and Beverage | $10,951.86 |
| Education | $149.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $46,774.54 | 2021-2025 | Opzelura, Opzelura |
| Lilly USA, LLC | $28,318.81 | 2022-2025 | Ebglyss, Taltz, Olumiant |
| Abbvie INC. | $27,672.18 | 2021-2025 | |
| Botanix Sb INC | $13,814.94 | 2025 | Sofdra |
| Eli Lilly and Company | $9,028.04 | 2023-2025 | Ebglyss, Olumiant |
| Boehringer Ingelheim Pharmaceuticals, INC. | $5,324.57 | 2022-2025 | Spevigo |
| Epi Health, LLC | $3,128.03 | 2022 | |
| Leo Pharma INC. | $2,875.80 | 2021-2025 | Anzupgo |
| Janssen Biotech, INC. | $1,701.47 | 2021-2025 | Tremfya |
| Pfizer INC. | $1,066.29 | 2022-2025 | |
| Dermavant Sciences, INC. | $1,009.81 | 2023-2024 | Vtama |
| Novartis Pharmaceuticals Corporation | $978.59 | 2021-2025 | |
| Genentech USA, INC. | $750.00 | 2023 | Xolair |
| E.R. Squibb & Sons, L.L.C. | $626.24 | 2021-2025 | Sotyktu |
| Journey Medical Corporation | $618.19 | 2022-2025 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Almirall LLC | $300.00 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $215.99 | 2021-2024 | Dupixent, Libtayo |
| Ucb, INC. | $167.25 | 2021-2025 | Bimzelx, Cimzia |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $139.92 | 2021-2024 | Cabtreo |
| Amgen INC. | $138.09 | 2025 | Otezla |
| Genzyme Corporation | $104.67 | 2022-2025 | |
| Organon LLC | $41.88 | 2025 | Vtama |
| Sun Pharmaceutical Industries INC. | $32.44 | 2025 | |
| Galderma Laboratories, L.P. | $26.08 | 2022 | |
| Tempus Ai, INC | $15.29 | 2024 | Merlin Test |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Francine Phillips listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.